FDA Likely To Take Holistic View Of AER Bill Compliance, Expert Says
This article was originally published in The Tan Sheet
Executive Summary
FDA will likely evaluate a company's compliance with adverse event reporting and record-keeping requirements on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center
You may also be interested in...
Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law
Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law
Experts Give AER Prep Course, Discuss Potential Potholes At UNPA Seminar
The implementation of the adverse event reporting bill will present the dietary supplement and nonprescription drug industries with challenges as well as opportunities, experts stressed at a recent United Natural Products Alliance seminar on the implementation of the new law